Newer immune checkpoint therapies that activate the T-cell immune response rather than block inhibition of T-cell activity including OX40 (CD134), OX40 ligand, and 41BB (CD137) may be able to enhance immune-associated anti-tumor activity in breast cancer. This evidence concerns the gene TNFRSF9 and breast carcinoma.